此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Deep Cervical Lymphovenous Anastomosis for Moderate Alzheimer's Disease (LYMVA-AD)

2026年6月13日 更新者:Rong Hu, MD、Southwest Hospital, China

The Efficacy and Safety of Deep Cervical LYMphatic-Venous Anastomosis for Moderate Alzheimer's Disease: A Multicenter, Prospective, Randomized Controlled Trial

This is a multicenter, prospective, open-label, endpoint-blinded randomized controlled clinical study. We aim to evaluate the safety and efficacy of deep cervical lymphovenous anastomosis (LVA) combined with routine treatment for patients with moderate Alzheimer's disease, compared with routine treatment alone.

A total of 296 eligible participants aged 50 to 80 years with moderate Alzheimer's disease will be enrolled and randomly divided into two groups at a 1:1 ratio. One group will receive deep cervical lymphovenous anastomosis plus standard routine treatment, while the other group will only receive standard routine treatment for Alzheimer's disease.

All participants will be followed up for 12 months after randomization. We will assess cognitive function using MMSE and CDR-SB scales, evaluate caregiver burden via ZBI scale, and detect changes in Alzheimer's disease related biomarkers including blood amyloid-beta and tau protein, as well as Aβ-PET imaging indicators. The main goal is to observe whether this surgical procedure can improve patients' neurological function and clear abnormal protein deposits in the brain, and confirm its long-term safety.

This study strictly follows ethical principles. Every participant or their legal representative will sign a written informed consent before enrollment. During the whole study period, we will closely monitor all adverse events to ensure the safety of participants.

研究概览

详细说明

Study Design and Objectives This is an interventional, multicenter, randomized, parallel-group, open-label and endpoint-blinded clinical trial. The primary objective is to verify the efficacy and safety of deep cervical lymphovenous anastomosis (LVA) in patients with moderate Alzheimer's disease. The secondary objectives include analyzing the changes of cognitive function, caregiver burden and cerebral amyloid-beta deposition within 12 months after intervention, and exploring the variation characteristics of peripheral blood biomarkers.

Study Population Eligible participants are patients diagnosed with probable Alzheimer's dementia consistent with 2011 NIA-AA clinical criteria and 2018 NIA-AA biomarker framework. Inclusion criteria: age 50 to 80 years; MMSE score between 10 and 20 points (moderate cognitive impairment); progressive cognitive decline for more than 6 months; no clinical improvement after more than six months of drug treatment; having a designated companion who can accompany follow-up and provide informed consent. Subjects with severe organ dysfunction, recent intracranial injury, drug allergy to study related reagents, PET contraindications or other severe mental disorders will be excluded.

Intervention and Control Measures Participants are randomly assigned to two groups by EDC system at a 1:1 ratio. Intervention group: Bilateral deep cervical lymphovenous anastomosis plus conventional symptomatic treatment for Alzheimer's disease. The operation is performed under surgical microscope with indocyanine green (ICG) lymphatic tracing technology. Postoperative routine anti-inflammatory treatment and rehabilitation training will be conducted.

Control group: Receive only standard drug treatment and routine rehabilitation training for Alzheimer's disease, without surgical intervention.

Evaluation Indicators and Time Points The primary outcome measure is the change of CDR-SB score from baseline to 12 months after randomization. Secondary outcome measures include changes in CDR-SB score at 1 month and 6 months, changes in MMSE and ZBI scores at 1, 6 and 12 months, and changes of Aβ-PET Centiloid value at 12 months. Exploratory indicators cover peripheral blood Aβ42, Aβ40, Aβ42/40 ratio, t-tau, p-tau and other biomarkers at each follow-up time point.

All assessments will be conducted at baseline, 1 month (±7 days), 6 months (±15 days) and 12 months (±15 days) after randomization. All adverse events, vital signs, laboratory tests, electrocardiogram and imaging findings will be continuously collected to evaluate the safety profile of the surgical procedure.

Randomization and Blinding Method Randomization is implemented via electronic data capture (EDC) system. Due to the nature of surgical intervention, participants, surgeons and clinical researchers cannot be blinded. However, all outcome assessors and statistical analysts are fully blinded to group allocation to reduce assessment bias. All raters will be shielded from patients' surgical scars during scale evaluation.

Statistical Analysis The full analysis set (FAS) will be adopted for primary efficacy analysis based on the intention-to-treat principle. Per-protocol set (PPS) will be used for sensitivity analysis, and safety analysis will be performed based on safety analysis set (SAS). Mixed-effects model for repeated measures (MMRM) and analysis of covariance (ANCOVA) will be applied for data analysis. Missing data will be handled by last observation carried forward (LOCF) method. Subgroup analyses stratified by APOEε4 status, age and baseline cognitive level will also be performed.

Ethical Requirements The whole study complies with the Declaration of Helsinki and relevant Chinese clinical research regulations. The study has been reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Army Medical University. Written informed consent will be obtained from each participant or their legal surrogate before any study-related procedures. Vulnerable population protection measures are strictly implemented for patients with cognitive impairment.

研究类型

介入性

注册 (估计的)

296

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国、400038
        • The First Affiliated Hospital of Army Medical University (Southwest Hospital)
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Aged 50 to 80 years old, male or female.
  • Clinically diagnosed with moderate probable Alzheimer's disease according to the NIA-AA criteria.
  • Baseline Mini-Mental State Examination (MMSE) score between 10 and 20 points.
  • Clinical cognitive decline duration of at least 6 months.
  • Stable routine anti-dementia drug treatment for more than 6 months without obvious clinical improvement.
  • Able to complete neuropsychological scale assessments, blood biomarker detection and Aβ-PET examination.
  • Have a reliable caregiver who can accompany follow-up visits and assist in completing evaluations.
  • The participant or legal surrogate voluntarily signs the written informed consent.

Exclusion Criteria:

  • Severe cardiac, hepatic, renal, respiratory or hematopoietic system dysfunction unable to tolerate surgery or anesthesia.
  • A history of intracranial surgery, severe craniocerebral trauma, stroke, brain tumor or other central nervous system diseases.
  • Other types of dementia, including vascular dementia, frontotemporal dementia, Lewy body dementia, or mixed dementia.
  • Psychiatric disorders requiring long-term medication that may affect cognitive assessment results.
  • Contraindications for PET imaging or contrast agent allergy.
  • Active infection, malignant tumor or severe wasting disease.
  • Pregnancy or breastfeeding status.
  • Participation in other interventional clinical trials within 3 months before enrollment.
  • Poor compliance or inability to complete scheduled follow-up.
  • Any other condition judged inappropriate for enrollment by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention Group (Surgery plus routine treatment)
Participants undergo bilateral deep cervical lymphovenous anastomosis (LVA), combined with standard routine drug treatment for moderate Alzheimer's disease.
A microsurgical lymphatic drainage procedure performed under operative microscope with ICG lymphography tracing. Bilateral deep cervical lymphovenous anastomosis is conducted to improve cerebral lymphatic clearance in patients with moderate Alzheimer's disease.
Participants receive only standard routine drug treatment for moderate Alzheimer's disease, with no surgical procedure performed.
有源比较器:Control Group (Routine treatment only)
Participants receive only standard routine drug treatment for moderate Alzheimer's disease, with no surgical procedure performed.
Participants receive only standard routine drug treatment for moderate Alzheimer's disease, with no surgical procedure performed.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in CDR-SB score from baseline to 12 months after randomization
大体时间:12 months after randomization
Change of Clinical Dementia Rating-Sum of Boxes (CDR-SB) score at 12 months compared with baseline, to evaluate overall cognitive and functional status of patients with moderate Alzheimer's disease.
12 months after randomization

次要结果测量

结果测量
措施说明
大体时间
Change in CDR-SB score at 1 month and 6 months after randomization
大体时间:1 month, 6 months after randomization
Serial changes of CDR-SB score at 1 month and 6 months post randomization.
1 month, 6 months after randomization
Change in MMSE score
大体时间:1 month, 6 months, 12 months after randomization
Change of Mini-Mental State Examination (MMSE) score reflecting general cognitive function.
1 month, 6 months, 12 months after randomization
Change in Zarit Burden Interview (ZBI) score
大体时间:1 month, 6 months, 12 months after randomization
Change of caregiver burden assessed by Zarit Burden Interview scale.
1 month, 6 months, 12 months after randomization
Change in Aβ-PET Centiloid value
大体时间:12 months after randomization
Variation of cerebral amyloid-beta deposition measured by Aβ-PET imaging.
12 months after randomization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2029年6月30日

研究注册日期

首次提交

2026年6月13日

首先提交符合 QC 标准的

2026年6月13日

首次发布 (实际的)

2026年6月22日

研究记录更新

最后更新发布 (实际的)

2026年6月22日

上次提交的符合 QC 标准的更新

2026年6月13日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • KY2026125
  • (A)KY2026125 (其他标识符:Ethics Committee of the First Affiliated Hospital of Army Medical University)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared externally to protect participants' personal privacy and comply with domestic clinical research regulations. All trial data are stored securely for internal use, inspection and audit only, and will not be provided to outside researchers without formal approval from the ethics committee.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅